A new treatment for ovarian cancer could prevent peritoneal recurrence, data suggests. 

Biotech company Oncoinvent is set to present results from the Phase I study of Radspherin after cytoreductive surgery in patients with platinums ensitivesensitive epithelial ovarian cancer. According to data released in advance, nine of 10 patients treated on the highest dose remained free from peritoneal recurrence at 24 months. 

Radspherin is an intraperitoneal alpha-emitting therapy targeting remaining cancer cells while sparing healthy tissue within the peritoneal cavity. The therapy addresses microscopic residual disease following cytoreductive surgery, preventing recurrence and enhancing long-term patient outcomes. 

Data released by Oncoinvent shows 21 patients were enrolled across dose levels with a favourable safety profile, with no dose-limiting toxicities observed. The full results will be presented at the European Society of Gynaecological Oncology (ESGO) 2026 Congress, taking place in Copenhagen, Denmark 26-28 February. 

“We are pleased to present our Phase I data at the ESGO 27th Annual Meeting, an important forum for sharing findings with the international gynaecologic oncology community,” said Yun Wang, who works at the Department for Cancer Surgery at Oslo University Hospital and who was the principal investigator in the trial. 

“These encouraging data reflect the collaborative efforts of the study team and the potential of Radspherin to address a patient population with high risk of peritoneal recurrence and poor prognosis.”